FindTrial
Sign In

SB1518

DRUG5 trials

Sponsors

S*BIO, M.D. Anderson Cancer Center

Conditions

Acute Myelogenous LeukemiaB Cell LymphomaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaHodgkin LymphomaHodgkin's LymphomaIndolent Lymphoma

Phase 1

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
CompletedNCT00719836
S*BIOAcute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia +2
Start: 2008-08-31End: 2012-01-31Updated: 2012-04-20
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
CompletedNCT00741871
S*BIOB Cell Lymphoma, Hodgkin's Lymphoma, Lymphoma, Malignant
Start: 2008-07-31End: 2011-10-31Updated: 2012-04-20
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
CompletedNCT00745550
S*BIOEssential Thrombocythemia, Myelofibrosis, Myeloproliferative Disorders +1
Start: 2008-08-31End: 2012-01-31Updated: 2012-04-20

Phase 2

A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
CompletedNCT01263899
S*BIOHodgkin Lymphoma, Indolent Lymphoma, Mantle Cell Lymphoma
Start: 2010-12-31End: 2012-02-29Updated: 2012-04-20
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
TerminatedNCT01436084
M.D. Anderson Cancer CenterLeukemia
Start: 2011-12-31End: 2013-06-30Updated: 2016-07-13

Related Papers

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
2016-12-0869 citations
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Blood2015-03-11117 citations